Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery | News Direct

Mindset Pharma discusses decision to expand into non-hallucinogenic drug discovery

News release by Mindset Pharma Inc

facebook icon linkedin icon twitter icon pinterest icon email icon Toronto | March 31, 2023 12:36 PM Eastern Daylight Time

Mindset Pharma CEO James Lanthier joins Proactive's Natalie Stoberman to discuss the company's latest update to expand into non-hallucinogenic therapeutic drug discovery.

Lanthier says Mindset has been one of the first biotech companies in the psychedelic space to apply state-of-the-art medicinal chemistry and behavioural pharmacology techniques to novel scaffolds of psychedelic drugs with the goal of discovering new medicines.

He adds that the company has been working towards discovering novel psychedelic-inspired non-hallucinogenic drug candidates and has found multiple candidates with a promising preclinical profile.

 

 

Contact Details

 

Proactive Canada

 

+1 604-688-8158

 

na-editorial@proactiveinvestors.com

Tags

proactiveinvestorsmindsetpharmaCSEMSETOTCQBMSSTFpsychedelicsnonhallucinogenicbiopharmatherapeuticsbiotechinvestinvestinginvestmentinvestorstockmarketstocksstockstockmarketnews